The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

But experts say the FDA should have no illusions regarding the unreliability of such surrogate outcomes, especially since these outcomes fail to take into account the harms a drug may cause, such as ...

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

While cancelled NIH grants and regulatory uncertainty are less hospitable to clinical research in the U.S., Europe must play ...

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health equity.

In response, in 2015 the Food and Drug Administration (FDA) launched a five-year action plan aimed at improving diversity in and transparency of pivotal clinical trials for newly approved drugs.

Now, a groundbreaking study from researchers at Boston Children’s Hospital and Harvard Medical School is offering a potential new path forward: using already FDA-approved migraine medications to ...